id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-E-1293-0006,FDA,FDA-2024-E-1293,Determination of Regulatory Review Period for Purposes of Patent Extension; ZELSUVMI,Notice,Determinations,2025-12-29T05:00:00Z,2025,12,2025-12-29T05:00:00Z,2026-02-28T04:59:59Z,2026-02-28T10:00:12Z,2025-23868,0,0,09000064b910a4a8
FDA-2024-E-1293-0005,FDA,FDA-2024-E-1293,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2025-08-19T04:00:00Z,2025,8,2025-08-19T04:00:00Z,,2025-08-19T21:44:37Z,,0,0,09000064b8f08598
FDA-2024-E-1293-0004,FDA,FDA-2024-E-1293,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-07-15T04:00:00Z,2025,7,2025-07-15T04:00:00Z,,2025-07-15T19:47:43Z,,0,0,09000064b8e73103
FDA-2024-E-1293-0003,FDA,FDA-2024-E-1293,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2025-06-30T04:00:00Z,2025,6,2025-06-30T04:00:00Z,,2025-06-30T16:06:59Z,,0,0,09000064b8e4576c
FDA-2024-E-1293-0001,FDA,FDA-2024-E-1293,Letter from U. S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-03-18T04:00:00Z,2024,3,2024-03-18T04:00:00Z,,2024-03-18T15:58:56Z,,0,0,090000648647dae1
FDA-2024-E-1293-0002,FDA,FDA-2024-E-1293,"Patent Term Extension Application for ZELSUVMI Patent No 9,855,211",Other,Application,2024-03-18T04:00:00Z,2024,3,2024-03-18T04:00:00Z,,2024-03-18T15:59:01Z,,0,0,090000648647dae3